DK2744515T3 - Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep - Google Patents
Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep Download PDFInfo
- Publication number
- DK2744515T3 DK2744515T3 DK12747923.6T DK12747923T DK2744515T3 DK 2744515 T3 DK2744515 T3 DK 2744515T3 DK 12747923 T DK12747923 T DK 12747923T DK 2744515 T3 DK2744515 T3 DK 2744515T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- combination therapy
- nitrogen mustard
- mustard
- nitrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| EP11177658 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US201261654097P | 2012-06-01 | 2012-06-01 | |
| PCT/EP2012/065906 WO2013024097A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2744515T3 true DK2744515T3 (da) | 2022-03-28 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12747923.6T DK2744515T3 (da) | 2011-08-16 | 2012-08-14 | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20140255427A1 (da) |
| EP (2) | EP2744515B1 (da) |
| JP (1) | JP6184952B2 (da) |
| KR (3) | KR20140064873A (da) |
| CN (1) | CN103732252B (da) |
| AU (1) | AU2012296907B2 (da) |
| BR (1) | BR112013033919B1 (da) |
| CA (2) | CA3137321A1 (da) |
| DK (1) | DK2744515T3 (da) |
| ES (1) | ES2909722T3 (da) |
| HR (1) | HRP20220228T1 (da) |
| HU (1) | HUE058350T2 (da) |
| IL (1) | IL230293B (da) |
| LT (1) | LT2744515T (da) |
| MX (1) | MX354479B (da) |
| PL (1) | PL2744515T3 (da) |
| PT (1) | PT2744515T (da) |
| RS (1) | RS63238B1 (da) |
| RU (1) | RU2625222C2 (da) |
| SG (1) | SG10201606785UA (da) |
| SI (1) | SI2744515T1 (da) |
| WO (1) | WO2013024097A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2951427A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| LT3302550T (lt) * | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| HUE056408T2 (hu) * | 2015-08-21 | 2022-02-28 | Morphosys Ag | Kombinációk és alkalmazásaik |
| AU2017244108B2 (en) | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| SI3465214T1 (sl) * | 2016-05-30 | 2021-12-31 | Morphosys Ag | Postopki za napovedovanje terapevtske koristi terapije proti CD19 pri pacientih |
| SG10202104036QA (en) * | 2016-10-28 | 2021-05-28 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| EP3630177B1 (en) * | 2017-05-31 | 2023-08-09 | MorphoSys AG | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| JP7460333B2 (ja) | 2019-06-13 | 2024-04-02 | タキロンシーアイ株式会社 | 化粧シート及び化粧シートの製造方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| SI1071752T1 (en) * | 1998-04-21 | 2003-12-31 | Micromet Ag | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US20060128777A1 (en) | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
| JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Ｃｄ１９抗体およびその使用法 |
| PT2270050E (pt) | 2005-12-30 | 2013-09-12 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| PT2059536E (pt) * | 2006-08-14 | 2014-04-14 | Xencor Inc | Anticorpos otimizados que visam cd19 |
| EP2066349B1 (en) | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
| ES2659517T3 (es) | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Métodos y composiciones para inhibir células que expresan CD32B |
| KR101658083B1 (ko) | 2007-10-19 | 2016-09-30 | 시애틀 지네틱스, 인크. | 씨디19 결합제 및 그의 용도 |
| JP2012515217A (ja) * | 2009-01-16 | 2012-07-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ベンダムスチンおよび抗−ｃｄ２０抗体の組合せを用いた癌治療 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| AU2010263272C1 (en) | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| NZ597325A (en) * | 2009-08-14 | 2014-03-28 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| WO2011057222A1 (en) * | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Application Discontinuation
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en active Application Filing
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active IP Right Grant
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko active Application Filing
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2744515T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| DK3502129T3 (da) | Konjugat omfattende oxyntomodulin og et immunoglobulinfragment og anvendelse deraf | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| DK2917790T3 (da) | Horologe med opbevaret og interchangeable face | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK2744826T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en purin-analog | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| DK2839860T3 (da) | Pyrrolobenzodiazepiner og konjugater deraf | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
| BR112014002219A2 (pt) | conjugados anticorpo p97 e métodos de sua utilização | |
| DK3339323T3 (da) | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf | |
| DK2950535T3 (da) | Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand | |
| IL231777A0 (en) | Antibodies against a1tl and their uses | |
| DK2718447T3 (da) | Managed ecosystem fermentation (mef) med vom og en nitrogenkilde | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| DK3173102T3 (da) | FGFR-FC-fusionsprotein og anvendelse deraf | |
| HK1200334A1 (en) | Combination therapy using immunoglobulin and c1-inhibitor c1- | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf |